Which account would you like to be logged in as?

Forgot Password?

Sign Up!

Visa/MasterCard and Discover Users
Flip your credit card over and look at the signature box. You should see either the entire 16-digit credit card number or just the last four digits followed by a special 3-digit code. The 3-digit code is your Card Security Code.

American Express Credit Card Users
Look for the 4-digit code printed on the front of your card just above and to the right of your main credit card number. The 4-digit code is your card Identification Number (CID).

What is a discount code?
Generic discount code text needs to go here

Webcast
aug 1
2012
Release date

Novel Approaches to Advanced Prostate Cancer: What Should We Target and Why?

Prostate Cancer

MEDIA: Webcast

Estimated time to complete activity: 1.5 hours | Release date: Wednesday, August 01, 2012 | Expiration date: Wednesday, July 31, 2013

INTRODUCTION

Novel Approaches to Advanced Prostate Cancer: What Should We Target and Why? provides participants with an overview of the most recent preclinical and clinical findings occurring in the field of androgen receptor targeted therapies in CRPC distilled into a concise learning opportunity by experts in the field that is intended to improve patient outcomes and health-related quality of life.

CHAIR


Adam S. Kibel, MD

Chief of Urologic Surgery
Brigham and Women's Hospital
Dana-Farber Cancer Institute
Professor of Surgery, Harvard University
Boston, Massachusetts

FACULTY


Stephen J. Freedland, MD

Attending Physician, Durham VA Medical Center
Associate Professor of Urology and Pathology
Duke Prostate Center
Duke University School of Medicine
Durham, North Carolina

Christopher J. Logothetis, MD

Chairman/Professor
Department of Genitourinary Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas

William K. Oh, MD

Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Mount Sinai School of Medicine
Associate Director of Clinical Research
The Tisch Cancer Institute
New York, New York

TARGET AUDIENCE

The intended audience for this activity includes practicing medical oncologists, urologists, and radiation oncologists caring for patients with CRPC.

EDUCATIONAL OBJECTIVES

At the conclusion of this activity, participants should be able to:

  • Evaluate the clinical course, incidence, and clinical criteria for the classification of castrate-resistant prostate cancer (CRPC)
  • Assess the role of the androgen receptor (AR) axis in prostate tumor biology and pathogenesis
  • Analyze the benefits and limitations for current and emerging treatment strategies targeting AR axis signaling events in CRPC
  • Discuss the impact of future treatment strategies and clinical trials on the treatment armamentarium for CRPC

PHYSICIAN CONTINUING EDUCATION

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of University Health Services Professional Education Programs (UHS-PEP) of Virginia Commonwealth University Health System and Educational Concepts Group, LLC (ECG). UHS-PEP is accredited by the ACCME to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT
UHS-PEP designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this activity. During the period Wednesday, August 01, 2012 through Wednesday, July 31, 2013, participants must 1) read the educational objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-activity assessment.

CME CREDITS

Physicians who complete the post-activity assessment with a score of 70% or better may view and print their credit letter via the website, www.educationalconcepts.net.

FACULTY LEADERS AND DISCLOSURE STATEMENT

All faculty participating in continuing education activities sponsored by University Health Services Professional Education Programs (UHS-PEP) and Educational Concepts Group, LLC (ECG) are expected to disclose to the audience any relevant financial relationships with commercial interests related to the content of their presentations/materials prior to the educational activity. All conflicts of interest have been resolved according to UHS-PEP's policies and procedures on conflicts of interest.

The Following Faculty Members Have Declared Relevant Financial Relationships

Adam S. Kibel, MD – Chair Honorarium Caris Life Sciences, Inc.
Dendreon Corporation
sanofi-aventis
Spectrum Pharmaceuticals, Inc.
Stephen J. Freedland, MD Consultant Fees Amgen Inc.
Dendreon Corporation
Janssen Biotech, Inc.
Honorarium Amgen Inc.
Janssen Biotech, Inc.
Speakers’ Bureau Amgen Inc.
Janssen Biotech, Inc.
Christopher J. Logothetis, MD Grants/Research Support Abbott Laboratories
American Bioscience, Inc.
Consultant Fees AstraZeneca
BiPar Sciences
Bristol-Myers Squibb Company
Speakers’ Bureau Boehringer Ingelheim
William K. Oh, MD Consultant Fees Amgen Inc.
Bellicum Pharmaceuticals, Inc.
Dendreon Corporation
Janssen Biotech, Inc.
Medivation, Inc.
Pfizer Inc
sanofi-aventis
Grants/Research Support Millennium: The Takeda Oncology Company

Staff Disclosure
Planners and managers at ECG have no relevant financial relationships to disclose.

DISCLOSURE OF OFF-LABEL USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ECG does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.

ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT

This activity is supported by educational grants from the following: Astellas Pharma US, Inc. and Medivation, Inc., Janssen Biotech, Inc., and Millennium: The Takeda Oncology Company

CME INQUIRIES

For further information, please contact:
Educational Concepts Group, LLC
1300 Parkwood Circle SE, Suite 325
Atlanta, Georgia 30339
Phone: 1.866.933.1681
Fax: 1.866.933.1692
www.educationalconcepts.net

None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net.

This activity is jointly sponsored by University Health Services Professional Education Programs (UHS-PEP) of Virginia Commonwealth University Health System and Educational Concepts Group, LLC (ECG).

Yes, I have read the information above and am interested in participating.

Proceed to Activity

More Online Activities